Developed by Shray Alag, The Harker School
Sections: Correlations,
Clinical Trials, and HPO
Navigate: Clinical Trials and HPO
| Name (Synonyms) | Correlation | |
|---|---|---|
| drug4222 | Video based exercise Wiki | 0.71 |
| drug2506 | Nasal swab Wiki | 0.50 |
| drug2512 | Nasopharyngeal swab Wiki | 0.25 |
| Name (Synonyms) | Correlation | |
|---|---|---|
| D007239 | Infection NIH | 0.03 |
| D018352 | Coronavirus Infections NIH | 0.03 |
| Name (Synonyms) | Correlation |
|---|
Navigate: Correlations HPO
There are 2 clinical trials
The main objectives of this study are 1) to establish the prevalence of SARS-CoV-2 in asymptomatic healthcare workers (HCWs) in an early phase of community spread as well as 2) to monitor the future spread of the disease by assessing serological responses to SARS-CoV-2 in symptomatic and asymptomatic HCWs over time and 3) to improve the assessment of the immune response and its protective effect as well as the assessment of infectivity of affected HCWs and 4) to evaluate the value and significance of antibody formation and serological antibody tests and 5) to be able to evaluate possible future preventive and / or therapeutic approaches against SARS-CoV-2
Description: Anti-SARS-COV2 S protein IgG ELISA
Measure: Number of people with detectable antibodies to SARS-COV2 Time: 1 yearDescription: SARS-COV2 PCR
Measure: Number of people with detectable SARS-COV2 nucleic acid Time: 1 yearDescription: Anti-SARS-COV2 S protein IgG ELISA
Measure: Number of people with detectable antibodies to SARS-COV2 Time: 2 yearsDescription: Anti-SARS-COV2 S protein IgG ELISA
Measure: Number of people with detectable antibodies to SARS-COV2 Time: 3 yearsDescription: Anti-SARS-COV2 S protein IgG ELISA
Measure: Number of people with detectable antibodies to SARS-COV2 Time: 4 yearsDescription: Anti-SARS-COV2 S protein IgG ELISA
Measure: Number of people with detectable antibodies to SARS-COV2 Time: 5 yearsDescription: SARS-COV2 PCR
Measure: Number of people with detectable SARS-COV2 nucleic acid Time: 2 yearsDescription: SARS-COV2 PCR
Measure: Number of people with detectable SARS-COV2 nucleic acid Time: 3 yearsDescription: SARS-COV2 PCR
Measure: Number of people with detectable SARS-COV2 nucleic acid Time: 4 yearsDescription: SARS-COV2 PCR
Measure: Number of people with detectable SARS-COV2 nucleic acid Time: 5 yearsThe main objectives of this study are 1. to establish the prevalence of SARS-CoV-2 in schools and kindergartens in the State of Mecklenburg-Vorpommern in autumn and winter 2020/2021 2. to monitor the future spread of the disease by assessing serological responses to SARS-CoV-2 in teachers and childcare educators over time
Description: Percentage of SARS-CoV-2 PCR positive participants (children and educational staff)
Measure: Share of participants with SARS-CoV-2 detectable in PCR Time: 5 monthsDescription: Percentage of Anti-SARS-COV2 S protein IgA and IgA ELISA positive participants (educational staff)
Measure: Seroprevalence of SARS-CoV-2 antibodies Time: At study inclusionDescription: Percentage of Anti-SARS-COV2 S protein IgA and IgA ELISA positive participants (educational staff)
Measure: Seroprevalence of SARS-CoV-2 antibodies Time: 5 monthsDescription: As assessed by a monthly questionnaire
Measure: SARS-CoV-2 risk factors, perceived risk of infection, and impact of the pandemic on quality of life Time: At study inclusionDescription: As assessed by a monthly questionnaire
Measure: SARS-CoV-2 risk factors, perceived risk of infection, and impact of the pandemic on quality of life Time: 1 monthDescription: As assessed by a monthly questionnaire
Measure: SARS-CoV-2 risk factors, perceived risk of infection, and impact of the pandemic on quality of life Time: 2 monthsDescription: As assessed by a monthly questionnaire
Measure: SARS-CoV-2 risk factors, perceived risk of infection, and impact of the pandemic on quality of life Time: 3 monthsDescription: As assessed by a monthly questionnaire
Measure: SARS-CoV-2 risk factors, perceived risk of infection, and impact of the pandemic on quality of life Time: 4 monthsDescription: As assessed by a monthly questionnaire
Measure: SARS-CoV-2 risk factors, perceived risk of infection, and impact of the pandemic on quality of life Time: 5 monthsDescription: Percentage of SARS-CoV-2 PCR positive participants (children and educational staff)
Measure: Share of participants with SARS-CoV-2 detectable in PCR Time: At study inclusionDescription: Percentage of SARS-CoV-2 PCR positive participants (children and educational staff)
Measure: Share of participants with SARS-CoV-2 detectable in PCR Time: 1 monthDescription: Percentage of SARS-CoV-2 PCR positive participants (children and educational staff)
Measure: Share of participants with SARS-CoV-2 detectable in PCR Time: 2 monthsDescription: Percentage of SARS-CoV-2 PCR positive participants (children and educational staff)
Measure: Share of participants with SARS-CoV-2 detectable in PCR Time: 3 monthsDescription: Percentage of SARS-CoV-2 PCR positive participants (children and educational staff)
Measure: Share of participants with SARS-CoV-2 detectable in PCR Time: 4 monthsAlphabetical listing of all HPO terms. Navigate: Correlations Clinical Trials
Data processed on September 26, 2020.
An HTML report was created for each of the unique drugs, MeSH, and HPO terms associated with COVID-19 clinical trials. Each report contains a list of either the drug, the MeSH terms, or the HPO terms. All of the terms in a category are displayed on the left-hand side of the report to enable easy navigation, and the reports contain a list of correlated drugs, MeSH, and HPO terms. Further, all reports contain the details of the clinical trials in which the term is referenced. Every clinical trial report shows the mapped HPO and MeSH terms, which are also hyperlinked. Related HPO terms, with their associated genes, protein mutations, and SNPs are also referenced in the report.
Drug Reports MeSH Reports HPO Reports